Christ cross

Caring Cross to present two posters at the 2022 American Society of Gene & Cell Therapy Annual Meeting

Research demonstrates that the newly defined CTAK mediates leukemia cell killing stems from the CAR-T manufacturing process itself

HIV suppression in a humanized mouse model, validating Caring Cross’ DuoCAR-T anti-HIV cell therapy

GAITHERSBURG, Md., May 16, 2022 /PRNewswire/ — Caring Cross, a 501c(3) nonprofit organization dedicated to accelerating the development of advanced medicines and enabling access to treatments for all patients, everywhere, announced that Rimas Orentas, Ph. .D., Scientific Director of Caring Cross, and Kim Anthony GondaPh.D., Director of Cell and Gene Therapy at Caring Cross, will present two posters at the 2022 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The meeting will be a hybrid event with online attendees and online. person in washington d.c.on May 16-22, 2022.

The poster details are as follows:

Poster 1

CAR T-Cell Antigen-Non-Specific Killing (CTAK), CAR-T NK-Like
Killing and CD22 CAR-T Mediated Killing are all powered by
Bryostatin treatment of pre-B acute lymphocytic leukemia cell
Lines

Session:

Cancer – Immunotherapy, Cancer Vaccines I

Card number :

M-213

Date:

May 16and2022

Weather:

1730-1830 EDT

Speaker:

Dr Rimas Orentas



Poster 2

Studies allowing IND for an open-label phase I/IIa trial for
To assess the safety and efficacy of the anti-HIV DuoCAR-T cell
Therapy

Session:

Ongoing gene and cell therapy trials

Card number :

Tu-299

Date:

May 17and2022

Weather:

1730-1830 EDT

Speaker:

Dr. Kim Anthony-Gonda

Register

https://annualmeeting.asgct.org/register

The first poster details the results of a study conducted in partnership with the University of Washington Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, which defined a novel property of chimeric antigen receptor (CAR-T) therapy. When CAR-T cells are activated by signals used to produce therapeutic cell populations, they have been shown to induce non-CAR-directed cytolysis, which the researchers termed antigen-nonspecific destruction of CAR T cells (CTAK). Importantly, the destruction mediated by the CAR-T manufacturing process is distinct from that exhibited by natural killer (NK) cells – white blood cells that target tumors and virus-infected cells – or activated killer cells. by lymphokine (LAK), those stimulated by cytokines alone to kill tumor cells.

“This discovery is an important step in our mission to increase the effectiveness of CAR-T therapies,” commented Dr. Orentas. “Increasing our knowledge of how bryostatin’s effects are disease-type specific, even in hematological malignancies, will aid our development of curative therapies.” Additionally, many of the side effects attributed to CAR-T may be due to CTAK activity. excited to share our findings at ASGCT and use this opportunity to collaborate with others and strengthen the efforts of the Caring Cross Network to provide point-of-care infrastructure for effective gene therapies in areas where they are most needed. required.

The second poster highlights the results of an IND-enabling study examining whether Caring Cross’ DuoCAR-T anti-HIV cell technology can travel to the spleens of humanized HIV-infected mice and inhibit virus replication. The study data concluded that intravenously administered anti-HIV DuoCAR-T cells traveled from peripheral blood to the spleen and demonstrated potent and long-lasting suppression of HIV replication after a single injection of anti-HIV DuoCAR cells. -T.

“It is Caring Cross’s mission to create accessible and curative therapies. There is currently no cure for HIV, only long-term drug therapies,” said Dr Anthony-Gonda. “Our DuoCAR-T anti-HIV cellular therapeutic candidate is designed to be a curative treatment option that eliminates HIV-infected cells and safely suppresses long-term HIV infection in the body after a single infusion of DuoCAR-T anti-HIV cells. are grateful to ASGCT for hosting our presentation, we are committed to furthering our technology in a phase 1/2a clinical trial. »

About the Benevolent Cross
Caring Cross is a 501(c)(3) nonprofit organization dedicated to accelerating the development of advanced medicines and ensuring access to treatments for all patients, everywhere. To carry out its mission, Caring Cross mobilizes a growing community of healthcare professionals, scientists, engineers, community advocates, donors, investors and business leaders to support the development of technologies and candidate drugs and technologies. Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability, and applicability of CAR-T technology and stem cell gene therapy. These opportunities include developing and implementing affordable solutions for manufacturing CAR-T cells, promoting a decentralized point-of-care cell manufacturing model, and developing its first therapeutic candidate, a cell therapy DuoCAR-T HIV drug designed to suppress HIV. replication and elimination of HIV-expressing cells in people living with HIV. Stem cell gene therapy for sickle cell disease and beta-thalassemia is also being developed. For more information about Caring Cross, visit https://caringcross.org/.

CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
862-213-1398
[email protected]

Media
Rosalyn Christian
862-353-9266
[email protected]

SOURCE Benevolent Cross